What is happening today is a knee-jerk reaction to the Pfizer news without any consideration given to the many indications that Brilacidin addresses, some of which you mentioned. In the short term it all comes down to successful trial results and an infusion of cash via grants, licensing deals or partnerships. That will put an end, once and for all, to our lack of broad investor recognition, then comes a nasdaq up-listing and institutional buyers partaking of big bites of IPIX. Success is at hand!
News 
Market Data 
Discover 
